NCT04829916View on ClinicalTrials.gov

A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

July 15, 2021

Study Completion Date

July 15, 2021

Conditions
Acute Kidney Injury (AKI)
Interventions
DRUG

RMC-035

Multiple dosing during 48 hours following cardiac surgery

DRUG

Placebo

Multiple dosing during 48 hours following cardiac surgery

Trial Locations (1)

DE-481 49

Münster University Hospital, Münster

Sponsors
All Listed Sponsors
lead

Guard Therapeutics AB

INDUSTRY

NCT04829916 - A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery | Biotech Hunter | Biotech Hunter